CoChat

Dipeptidyl Peptidase‐4 Inhibitors and Cardiovascular Outcomes: Meta‐Analysis of Randomized Clinical Trials with 55,141 Participants

Wu, Shiying, Hopper, Ingrid, Skiba, Marina, Krum, Henry · 2014 · Cardiovascular Therapeutics
Cited by 129

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Aims: The association between glucose lowering in diabetes mellitus and major cardiovascular (CV) outcomes is weak; indeed, some oral hypoglycemic agents are associated with increased CV events. Dipeptidyl peptidase‐4 inhibitors (DPP‐4 inhibitors) are a new class of oral hypoglycemic agent that may have beneficial CV effects. We undertook a systematic review and meta‐analysis to appraise the CV safety and efficacy of DPP‐4 inhibitors. Methods: Comprehensive search for prospective trials involving DPP‐4 inhibitors. Trials included reported at least one of the outcomes examined, recruited minimum 100 patients and minimum follow‐up 24 weeks. The risk ratio (RR) was calculated using the M antel–H aenszel random‐effects model for mortality and major cardiovascular (CV) outcomes. Results: Fifty trials enrolling 55,141 participants were included. Mean follow‐up 45.3 weeks. DPP‐4 inhibitors compared with all comparators (placebo and active) showed no difference in all‐cause mortality (n = 50,982, RR = 1.01, 95% CI 0.91–1.13, P = 0.83), CV mortality (n = 48,151, RR = 0.97, 95% CI 0.85–1.11, P = 0.70), acute coronary syndrome (ACS) (n = 53,034 RR = 0.97, 95% CI 0.87–1.08, P = 0.59), or stroke (n = 42,737, RR = 0.98, 95% CI 0.81–1.18, P = 0.80), and a statistically significant increase in heart failure outcomes (n = 39,953, RR = 1.16, 95% CI 1.01–1.33, P = 0.04). Discussion: Treatment with DPP‐4 inhibitors compared with placebo shows no increase in risk with regards to all‐cause mortality, CV mortality, ACS, or stroke, but a statistically significant trend toward increased risk of HF outcomes. Conclusion: These findings suggest no cardiovascular harm (or benefit) with DPP‐4 inhibitors; further large‐scale CV outcome studies will resolve the issue of excess HF risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/1755-5922.12075

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 129

Metadata

Authors
Wu, S., Hopper, I., Skiba, M., & Krum, H.
Venue
Cardiovascular Therapeutics
Publisher
Wiley
Published
2014-07-09
Volume
32
Issue
4
Pages
147-158
ISSN
  • 1755-5914 (ISSN-L)
  • 1755-5922
OpenAlex
W2063362369
Cited by
129
References
8
FWCI
19.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dipeptidyl Peptidase‐4 Inhibitors and Cardiovascular Outcomes: Meta‐Analysis of Randomized Clinical Trials with 55,141 Participants. https://app.cochat.ai/papers/10.1111/1755-5922.12075
The paper
Wu, S., Hopper, I., Skiba, M., & Krum, H. (2014). Dipeptidyl Peptidase‐4 Inhibitors and Cardiovascular Outcomes: Meta‐Analysis of Randomized Clinical Trials with 55,141 Participants. Cardiovascular Therapeutics. https://doi.org/10.1111/1755-5922.12075

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.